**Question:** Best treatment of refractory peri-anal fistula in Crohn's disease:

**Core Concept:**
Perianal fistulas are communication channels between the gastrointestinal tract and the skin surrounding the anus, commonly seen in patients with Crohn's disease. Refractory perianal fistulas are those that do not respond to conventional treatments. In such cases, appropriate management aims to control infection, prevent abscess formation, and achieve long-term closure of the fistula tract.

**Why the Correct Answer is Right:**

Correct Answer: **D. Infliximab (anti-tumor necrosis factor-alpha)**

Infliximab is a monoclonal antibody that targets and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in the pathogenesis of Crohn's disease and perianal fistulas. By suppressing TNF-alpha, infliximab helps reduce inflammation and promote healing of the involved fistula tract.

**Why Each Wrong Option is Incorrect:**

A. **Adalimumab (anti-TNF-alpha)**
This option is incorrect as adalimumab is a different monoclonal antibody targeting TNF-alpha. Although both drugs may have similar efficacy in treating perianal fistulas, they are not identical molecules, and small variations in drug properties can lead to differences in clinical outcomes.

B. **Surgical intervention**
While surgical intervention like fistulotomy, seton placement, or fistulectomy may be necessary in some cases, they are not the primary treatment option for refractory perianal fistulas. Infliximab, being a biological therapy, provides a more systemic approach to controlling inflammation and promoting healing, which is crucial in refractory cases.

C. **Antibiotics**
Antibiotics are essential for managing perianal fistulas as they help control local infection. However, they are not sufficient as a standalone treatment for refractory perianal fistulas, as they fail to address the underlying inflammatory process caused by TNF-alpha.

**Clinical Pearl:**

Infliximab, a monoclonal antibody targeting TNF-alpha, is a more comprehensive treatment for refractory perianal fistulas in Crohn's disease patients compared to surgical intervention or antibiotics alone. This biological therapy helps control inflammation, prevent abscess formation, and promote fistula tract closure, resulting in improved outcomes in these challenging cases.